Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

H. Yang, C. Bueso-Ramos, C. Dinardo, M. R. Estecio, M. Davanlou, Q. R. Geng, Z. Fang, M. Nguyen, S. Pierce, Y. Wei, S. Parmar, J. Cortes, H. Kantarjian, G. Garcia-Manero

Research output: Contribution to journalArticle

Abstract

Blockade of immune checkpoints is emerging as a new form of anticancer therapy. We studied the expression of programmed death ligand 1 (PD-L1), PD-L2, programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) mRNA in CD34+ cells from myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) patients (N=124). Aberrant upregulation (≥2-fold) was observed in 34, 14, 15 and 8% of the patients. Increased expression of these four genes was also observed in peripheral blood mononuclear cells (PBMNCs) (N=61). The relative expression of PD-L1 from PBMNC was significantly higher in MDS (P=0.018) and CMML (P=0.0128) compared with AML. By immunohistochemical analysis, PD-L1 protein expression was observed in MDS CD34+ cells, whereas stroma/non-blast cellular compartment was positive for PD-1. In a cohort of patients treated with epigenetic therapy, PD-L1, PD-L2, PD-1 and CTLA4 expression was upregulated. Patients resistant to therapy had relative higher increments in gene expression compared with patients who achieved response. Treatment of leukemia cells with decitabine resulted in a dose-dependent upregulation of above genes. Exposure to decitabine resulted in partial demethylation of PD-1 in leukemia cell lines and human samples. This study suggests that PD-1 signaling may be involved in MDS pathogenesis and resistance mechanisms to hypomethylating agents. Blockade of this pathway can be a potential therapy in MDS and AML.

Original languageEnglish (US)
Pages (from-to)1280-1288
Number of pages9
JournalLeukemia
Volume28
Issue number6
DOIs
StatePublished - Jun 2014
Externally publishedYes

Fingerprint

Programmed Cell Death 1 Ligand 2 Protein
CTLA-4 Antigen
Myelodysplastic Syndromes
decitabine
Acute Myeloid Leukemia
Leukemia, Myelomonocytic, Chronic
Therapeutics
Blood Cells
Leukemia
Up-Regulation
Ligands
Gene Expression
Epigenomics

Keywords

  • DNA methylation
  • myelodysplastic syndromes
  • programmed death-1

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Yang, H., Bueso-Ramos, C., Dinardo, C., Estecio, M. R., Davanlou, M., Geng, Q. R., ... Garcia-Manero, G. (2014). Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia, 28(6), 1280-1288. https://doi.org/10.1038/leu.2013.355

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. / Yang, H.; Bueso-Ramos, C.; Dinardo, C.; Estecio, M. R.; Davanlou, M.; Geng, Q. R.; Fang, Z.; Nguyen, M.; Pierce, S.; Wei, Y.; Parmar, S.; Cortes, J.; Kantarjian, H.; Garcia-Manero, G.

In: Leukemia, Vol. 28, No. 6, 06.2014, p. 1280-1288.

Research output: Contribution to journalArticle

Yang, H, Bueso-Ramos, C, Dinardo, C, Estecio, MR, Davanlou, M, Geng, QR, Fang, Z, Nguyen, M, Pierce, S, Wei, Y, Parmar, S, Cortes, J, Kantarjian, H & Garcia-Manero, G 2014, 'Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents', Leukemia, vol. 28, no. 6, pp. 1280-1288. https://doi.org/10.1038/leu.2013.355
Yang, H. ; Bueso-Ramos, C. ; Dinardo, C. ; Estecio, M. R. ; Davanlou, M. ; Geng, Q. R. ; Fang, Z. ; Nguyen, M. ; Pierce, S. ; Wei, Y. ; Parmar, S. ; Cortes, J. ; Kantarjian, H. ; Garcia-Manero, G. / Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. In: Leukemia. 2014 ; Vol. 28, No. 6. pp. 1280-1288.
@article{f6cfcd3434fb4fe4811d0a758bccbf29,
title = "Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents",
abstract = "Blockade of immune checkpoints is emerging as a new form of anticancer therapy. We studied the expression of programmed death ligand 1 (PD-L1), PD-L2, programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) mRNA in CD34+ cells from myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) patients (N=124). Aberrant upregulation (≥2-fold) was observed in 34, 14, 15 and 8{\%} of the patients. Increased expression of these four genes was also observed in peripheral blood mononuclear cells (PBMNCs) (N=61). The relative expression of PD-L1 from PBMNC was significantly higher in MDS (P=0.018) and CMML (P=0.0128) compared with AML. By immunohistochemical analysis, PD-L1 protein expression was observed in MDS CD34+ cells, whereas stroma/non-blast cellular compartment was positive for PD-1. In a cohort of patients treated with epigenetic therapy, PD-L1, PD-L2, PD-1 and CTLA4 expression was upregulated. Patients resistant to therapy had relative higher increments in gene expression compared with patients who achieved response. Treatment of leukemia cells with decitabine resulted in a dose-dependent upregulation of above genes. Exposure to decitabine resulted in partial demethylation of PD-1 in leukemia cell lines and human samples. This study suggests that PD-1 signaling may be involved in MDS pathogenesis and resistance mechanisms to hypomethylating agents. Blockade of this pathway can be a potential therapy in MDS and AML.",
keywords = "DNA methylation, myelodysplastic syndromes, programmed death-1",
author = "H. Yang and C. Bueso-Ramos and C. Dinardo and Estecio, {M. R.} and M. Davanlou and Geng, {Q. R.} and Z. Fang and M. Nguyen and S. Pierce and Y. Wei and S. Parmar and J. Cortes and H. Kantarjian and G. Garcia-Manero",
year = "2014",
month = "6",
doi = "10.1038/leu.2013.355",
language = "English (US)",
volume = "28",
pages = "1280--1288",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

AU - Yang, H.

AU - Bueso-Ramos, C.

AU - Dinardo, C.

AU - Estecio, M. R.

AU - Davanlou, M.

AU - Geng, Q. R.

AU - Fang, Z.

AU - Nguyen, M.

AU - Pierce, S.

AU - Wei, Y.

AU - Parmar, S.

AU - Cortes, J.

AU - Kantarjian, H.

AU - Garcia-Manero, G.

PY - 2014/6

Y1 - 2014/6

N2 - Blockade of immune checkpoints is emerging as a new form of anticancer therapy. We studied the expression of programmed death ligand 1 (PD-L1), PD-L2, programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) mRNA in CD34+ cells from myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) patients (N=124). Aberrant upregulation (≥2-fold) was observed in 34, 14, 15 and 8% of the patients. Increased expression of these four genes was also observed in peripheral blood mononuclear cells (PBMNCs) (N=61). The relative expression of PD-L1 from PBMNC was significantly higher in MDS (P=0.018) and CMML (P=0.0128) compared with AML. By immunohistochemical analysis, PD-L1 protein expression was observed in MDS CD34+ cells, whereas stroma/non-blast cellular compartment was positive for PD-1. In a cohort of patients treated with epigenetic therapy, PD-L1, PD-L2, PD-1 and CTLA4 expression was upregulated. Patients resistant to therapy had relative higher increments in gene expression compared with patients who achieved response. Treatment of leukemia cells with decitabine resulted in a dose-dependent upregulation of above genes. Exposure to decitabine resulted in partial demethylation of PD-1 in leukemia cell lines and human samples. This study suggests that PD-1 signaling may be involved in MDS pathogenesis and resistance mechanisms to hypomethylating agents. Blockade of this pathway can be a potential therapy in MDS and AML.

AB - Blockade of immune checkpoints is emerging as a new form of anticancer therapy. We studied the expression of programmed death ligand 1 (PD-L1), PD-L2, programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) mRNA in CD34+ cells from myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) patients (N=124). Aberrant upregulation (≥2-fold) was observed in 34, 14, 15 and 8% of the patients. Increased expression of these four genes was also observed in peripheral blood mononuclear cells (PBMNCs) (N=61). The relative expression of PD-L1 from PBMNC was significantly higher in MDS (P=0.018) and CMML (P=0.0128) compared with AML. By immunohistochemical analysis, PD-L1 protein expression was observed in MDS CD34+ cells, whereas stroma/non-blast cellular compartment was positive for PD-1. In a cohort of patients treated with epigenetic therapy, PD-L1, PD-L2, PD-1 and CTLA4 expression was upregulated. Patients resistant to therapy had relative higher increments in gene expression compared with patients who achieved response. Treatment of leukemia cells with decitabine resulted in a dose-dependent upregulation of above genes. Exposure to decitabine resulted in partial demethylation of PD-1 in leukemia cell lines and human samples. This study suggests that PD-1 signaling may be involved in MDS pathogenesis and resistance mechanisms to hypomethylating agents. Blockade of this pathway can be a potential therapy in MDS and AML.

KW - DNA methylation

KW - myelodysplastic syndromes

KW - programmed death-1

UR - http://www.scopus.com/inward/record.url?scp=84902075577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902075577&partnerID=8YFLogxK

U2 - 10.1038/leu.2013.355

DO - 10.1038/leu.2013.355

M3 - Article

C2 - 24270737

AN - SCOPUS:84902075577

VL - 28

SP - 1280

EP - 1288

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 6

ER -